Table 3 List of differentially sialylated glycopeptides identified and quantitated in ovarian cancer and prostate cancer sera
Swissprot ID | Protein | Glycopeptide sequence | Heavy/Light ratio (peptide) | Â |
|---|---|---|---|---|
Ovarian cancer | Prostate cancer | |||
increase of sialylation in ovarian cancer and prostate cancer | ||||
P00738 | Haptoglobin | NLFLNHS ENAT AK | 2.0 | 3.1 |
| Â | Â | VVLHPNYS QVDIGLIK | 2.7 | 3.8 |
P00450 | Ceruloplasmin | EHEGAIYPDNTT DFQR | 3.1 | 3.9 |
P02790 | Hemopexin | ALPQPQNVT SLLGCTH | 2.1 | 3.8 |
P04114 | Apolipoprotein B-100 | FVEGSHNST VSLTTK | 2.0 | 2.9 |
P01009 | Isoform 1 of Alpha-1-antitrypsin | YLGNAT AIFFLPDEGK | 2.1 | 5.5 |
increase of sialylation only in ovarian cancer | ||||
P27169 | Serum paraoxonase/arylesterase 1 | HANWT LTPLK | 4.0 | â–¬ |
P02787 | Serotransferrin | CGLVPVLAENYNK | 7.6 | 1.1 |
| Â | Â | QQQHLFGSNVT DCSGNFCLFR | 3.1 | â–¬ |
O75882 | Attractin | NHS CSEGQISIFR | 2.2 | â–¬ |
P25311 | Zinc-alpha-2-glycoprotein | DIVEYYNDSNGSHVLQGR | 2.0 | â–¬ |
increase of sialylation only in prostate cancer | ||||
P36980 | Complement factor H-related protein 1 | LQNNENNIS CVER | 1.8 | 2.2 |
P19823 | Inter-alpha-trypsin inhibitor heavy chain H2 | GAFISNFS MTVDGK | 1.0 | 4.2 |
P08603 | Isoform 1 of Complement factor H | IPCSQPPQIEHGTINSS R | 1.9 | 3.5 |
| Â | Â | ISEENETTCYMGK | â–¬ | 2.8 |
| Â | Â | MDGASNVT CINSR | 1.0 | 2.3 |
P04004 | Vitronectin | NNATVHEQVGGPSLTSDLQAQSK | â–¬ | 2.4 |
P02765 | Alpha-2-HS-glycoprotein | AALAAFNAQNNGS NFQLEEISR | 1.6 | 3.7 |
| Â | Â | KVCQDCPLLAPLNDT R | 1.1 | 4.3 |
| Â | Â | VCQDCPLLAPLNDT R | 1.3 | 2.4 |
P02763 | Alpha-1-acid glycoprotein 1 | QDQCIYNTT YLNVQR | 1.8 | 2.1 |
P00450 | Ceruloplasmin | ENLT APGSDSAVFFEQGTTR | 1.9 | 3.1 |
| Â | Â | AGLQAFFQVQECNK | 0.4 | 6.8 |
P02790 | Hemopexin | SWPAVGNCS SALR | 1.6 | 4.4 |
P27169 | Serum paraoxonase/arylesterase 1 | VTQVYAENGT VLQGSTVASVYK | â–¬ | 2.1 |
P01042 | Isoform HMW of Kininogen-1 | ITYSIVQTNCS K | 1.6 | 2.5 |
| Â | Â | LNAENNAT FYFK | 1.2 | 5.0 |
P01871 | IGHM protein | GLTFQQNAS SMCVPDQDTAIR | â–¬ | 4.7 |
| Â | Â | YKNNS DISSTR | â–¬ | 2.3 |
increase of sialylation in ovarian cancer and prostate cancer | ||||
P00738 | Haptoglobin | NLFLNHS ENAT AK | 2.0 | 3.1 |
| Â | Â | VVLHPNYS QVDIGLIK | 2.7 | 3.8 |
P00450 | Ceruloplasmin | EHEGAIYPDNTT DFQR | 3.1 | 3.9 |
P02790 | Hemopexin | ALPQPQNVT SLLGCTH | 2.1 | 3.8 |
P04114 | Apolipoprotein B-100 | FVEGSHNST VSLTTK | 2.0 | 2.9 |
P01009 | Isoform 1 of Alpha-1-antitrypsin | YLGNAT AIFFLPDEGK | 2.1 | 5.5 |
increase of sialylation only in ovarian cancer | ||||
P27169 | Serum paraoxonase/arylesterase 1 | HANWT LTPLK | 4.0 | â–¬ |
P02787 | Serotransferrin | CGLVPVLAENYNK | 7.6 | 1.1 |
| Â | Â | QQQHLFGSNVT DCSGNFCLFR | 3.1 | â–¬ |
O75882 | Attractin | NHS CSEGQISIFR | 2.2 | â–¬ |
P25311 | Zinc-alpha-2-glycoprotein | DIVEYYNDS NGSHVLQGR | 2.0 | â–¬ |
increase of sialylation only in prostate cancer | ||||
P36980 | Complement factor H-related protein 1 | LQNNENNIS CVER | 1.8 | 2.2 |
P19823 | Inter-alpha-trypsin inhibitor heavy chain H2 | GAFISNFS MTVDGK | 1.0 | 4.2 |
P08603 | Isoform 1 of Complement factor H | IPCSQPPQIEHGTINSS R | 1.9 | 3.5 |
| Â | Â | ISEENET TCYMGK | â–¬ | 2.8 |
| Â | Â | MDGASNVT CINSR | 1.0 | 2.3 |
P04004 | Vitronectin | NNAT VHEQVGGPSLTSDLQAQSK | â–¬ | 2.4 |
P02765 | Alpha-2-HS-glycoprotein | AALAAFNAQNNGS NFQLEEISR | 1.6 | 3.7 |
| Â | Â | KVCQDCPLLAPLNDT R | 1.1 | 4.3 |
| Â | Â | VCQDCPLLAPLNDT R | 1.3 | 2.4 |
P02763 | Alpha-1-acid glycoprotein 1 | QDQCIYNTT YLNVQR | 1.8 | 2.1 |
P00450 | Ceruloplasmin | ENLT APGSDSAVFFEQGTTR | 1.9 | 3.1 |
| Â | Â | AGLQAFFQVQECNK | 0.4 | 6.8 |
P02790 | Hemopexin | SWPAVGNCS SALR | 1.6 | 4.4 |
P27169 | Serum paraoxonase/arylesterase 1 | VTQVYAENGT VLQGSTVASVYK | â–¬ | 2.1 |
P01042 | Isoform HMW of Kininogen-1 | ITYSIVQTNCS K | 1.6 | 2.5 |
| Â | Â | LNAENNAT FYFK | 1.2 | 5.0 |
P01871 | IGHM protein | GLTFQQNAS SMCVPDQDTAIR | â–¬ | 4.7 |
| Â | Â | YKNNS DISSTR | â–¬ | 2.3 |